Product Name: MDV3100 (Enzalutamide) | AR antagonist
Product Description: MDV3100 (Enzalutamide) is an orally-available thioxoimidazoline androgen receptor antagonist approved in August, 2012, for the treatment of castration-resistant prostate cancer (CRPC). In LNCaP/AR cells, MDV3100 has a potency of 36 nM. [1] MDV3100 blocks Web Site：Medchemexpress
Chemical Formula: C21H16F4N4O2S
Molecular Weight: 464.44
‘&“CAS NO: 1234015-54-3 LY2606368 (dihydrochloride)
Purity: 99%
Appearance: White
Chemical Name: 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamideEAAT2 inhibitors
Solubility: Up to 100 mM in DMSO
Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage Condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/21300059
